- Home
- RHI vs DNLI Comparison
RHI vs DNLI Comparison
Compare RHI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RHI | DNLI |
|---|---|---|
| Founded | 1948 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RHI | DNLI |
|---|---|---|
| Price | $27.26 | $21.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $36.00 | $31.58 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $5,378,506,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.76 | $3,975.30 |
| P/E Ratio | $20.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.22 | $10.57 |
| 52 Week High | $70.35 | $24.35 |
Technical Indicators
Market Signals| Indicator | RHI | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 68.53 |
| Support Level | $26.76 | $20.35 |
| Resistance Level | $29.31 | $21.39 |
| Average True Range (ATR) | 1.08 | 1.14 |
| MACD | -0.14 | 0.38 |
| Stochastic Oscillator | 23.88 | 92.05 |
Price Performance
Historical ComparisonAbout RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.